Ovalbumin peptide–major histocompatibility complex class II complex (OVA–MHC class II complex)

The Ovalbumin peptide–MHC class II complex forms when a peptide fragment from ovalbumin (most commonly OVA 323–339: ISQAVHAAHAEINEAGR), is bound by an MHC class II molecule (such as I-A(d) in mice), creating a complex that is presented on the surface of antigen-presenting cells for recognition by CD4+ T cells[5][8][9]. This system is a cornerstone of experimental immunology, enabling examination of antigen processing, presentation mechanisms, specificity of T cell responses, and how different peptide registers modulate immune activation[8][9]. The complex does not occur naturally in humans but is widely used as a surrogate antigen system in research to study fundamental principles that underpin therapeutic targeting of MHC-peptide interactions and immune modulation. Variants and modifications (e.g., with β-amino acids or conjugated to antibodies) are investigated to assess how peptide structure influences MHC binding, stability, processing, and T cell stimulation[4][5][8]. Key references are studies of the crystal structure, binding registers, and mechanisms by which this model antigen drives T cell responses in mice, as well as its utility in dissecting the biochemistry and cell biology of MHC class II antigen presentation[5][8][9].

Other names

OVA–I-A(d) complexOvalbumin(323–339)–I-A(d) complexOVA peptide–class II MHC complexOVA 323–339–I-A(d) complexOVA–MHC-II complexMHC-II–ovalbumin peptide complex

There is no direct drug mechanism for this complex itself, but modified peptides (e.g., those with β-amino acids or conjugated antibody fragments) may alter stability, MHC binding, and T cell stimulatory capacity for experimental purposes